• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲3级生物安全实验室的生物安全与生物安保:聚焦法国近期进展及基本要求

Biosafety and Biosecurity in European Containment Level 3 Laboratories: Focus on French Recent Progress and Essential Requirements.

作者信息

Pastorino Boris, de Lamballerie Xavier, Charrel Rémi

机构信息

UMR "Emergence des Pathologies Virales" (EPV: Aix-Marseille Univ - IRD 190 - Inserm 1207 - EHESP - IHU Méditerranée Infection), Marseille, France.

UMR 190 "Emergence des Pathologies Virales", Virology, 19-21 bd jean moulin faculté de medecine de la timone, Institut hospitalo-universitaire Méditerranée infection, APHM Public Hospitals of Marseille, Marseille, France.

出版信息

Front Public Health. 2017 May 31;5:121. doi: 10.3389/fpubh.2017.00121. eCollection 2017.

DOI:10.3389/fpubh.2017.00121
PMID:28620600
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5449436/
Abstract

Even if European Union (EU) Member States are obliged to implement EU Directives 2000/54/EC , national biosafety regulations and practices varied from country to country. In fact, EU legislation on biological agents and genetically modified microorganisms is often not specific enough to ensure harmonization leading to difficulties in implementation for most laboratories. In the same way, biosecurity is a relatively new concept and a few EU Member States are known to have introduced national laboratory biosecurity legislation. In France, recent regulations have reinforced biosafety/biosecurity in containment level 3 (CL-3) laboratories but they concern a specific list of pathogens with no correlation in other European Members States. The objective of this review was to summarize European biosafety/biosecurity measures concerning CL-3 facilities focusing on French specificities. Essential requirements needed to preserve efficient biosafety measures when manipulating risk group 3 biological agents are highlighted. In addition, International, European and French standards related to containment laboratory planning, operation or biosafety equipment are described to clarify optimal biosafety and biosecurity requirements.

摘要

即使欧盟成员国必须执行欧盟第2000/54/EC号指令,但各国的国家生物安全法规和做法仍存在差异。事实上,欧盟关于生物制剂和转基因微生物的立法往往不够具体,无法确保协调一致,这给大多数实验室的实施带来了困难。同样,生物安全是一个相对较新的概念,已知只有少数欧盟成员国出台了国家实验室生物安全立法。在法国,最近的法规加强了三级防护实验室(CL-3)的生物安全/生物安保,但这些法规涉及的是一份特定的病原体清单,与其他欧洲成员国没有关联。本综述的目的是总结欧洲关于CL-3设施的生物安全/生物安保措施,重点关注法国的特殊性。强调了在处理风险等级为3的生物制剂时保持有效生物安全措施所需的基本要求。此外,还描述了与防护实验室规划、操作或生物安全设备相关的国际、欧洲和法国标准,以阐明最佳的生物安全和生物安保要求。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdd4/5449436/cbc5231018ff/fpubh-05-00121-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdd4/5449436/2424da83adac/fpubh-05-00121-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdd4/5449436/cbc5231018ff/fpubh-05-00121-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdd4/5449436/2424da83adac/fpubh-05-00121-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdd4/5449436/cbc5231018ff/fpubh-05-00121-g002.jpg

相似文献

1
Biosafety and Biosecurity in European Containment Level 3 Laboratories: Focus on French Recent Progress and Essential Requirements.欧洲3级生物安全实验室的生物安全与生物安保:聚焦法国近期进展及基本要求
Front Public Health. 2017 May 31;5:121. doi: 10.3389/fpubh.2017.00121. eCollection 2017.
2
Comparison of Brazilian High- and Maximum-Containment Laboratories Biosafety and Biosecurity Regulations to Legal Frameworks in the United States and Other Countries: Gaps and Opportunities.巴西高防护和最高防护实验室生物安全与生物安保法规与美国及其他国家法律框架的比较:差距与机遇
Appl Biosaf. 2024 Mar 1;29(1):45-56. doi: 10.1089/apb.2023.0005. Epub 2024 Feb 28.
3
The hidden face of academic researches on classified highly pathogenic microorganisms.关于高致病性分类微生物学术研究的隐藏面。
Infect Genet Evol. 2015 Jan;29:26-34. doi: 10.1016/j.meegid.2014.10.028. Epub 2014 Nov 7.
4
Harmonization of Biosafety and Biosecurity Standards for High-Containment Facilities in Low- and Middle-Income Countries: An Approach From the Perspective of Occupational Safety and Health.低收入和中等收入国家高防护实验室生物安全与生物安保标准的协调统一:职业安全与健康视角下的一种方法
Front Public Health. 2019 Sep 12;7:249. doi: 10.3389/fpubh.2019.00249. eCollection 2019.
5
A Multilingual Tool for Standardized Laboratory Biosafety and Biosecurity Assessment and Monitoring.一种用于标准化实验室生物安全和生物安保评估和监测的多语言工具。
Health Secur. 2022 Nov-Dec;20(6):488-496. doi: 10.1089/hs.2022.0030. Epub 2022 Nov 16.
6
Biosafety and Biosecurity in Containment: A Regulatory Overview.密闭环境中的生物安全与生物安保:监管概述
Front Bioeng Biotechnol. 2020 Jun 30;8:650. doi: 10.3389/fbioe.2020.00650. eCollection 2020.
7
Improved Biosafety and Biosecurity Measures and/or Strategies to Tackle Laboratory-Acquired Infections and Related Risks.改进生物安全和生物安保措施和/或策略,以应对实验室获得性感染和相关风险。
Int J Environ Res Public Health. 2018 Nov 29;15(12):2697. doi: 10.3390/ijerph15122697.
8
Mobile High-Containment Biological Laboratories Deployment: Opportunities and Challenges in Expeditionary Deployments to Outbreak Response.移动高防护生物实验室的部署:疫情应对远征部署中的机遇与挑战
Appl Biosaf. 2019 Mar 1;24(1):20-29. doi: 10.1177/1535676018818563.
9
Improving U.S. Biosafety and Biosecurity: Revisiting Recommendations from the Federal Experts Security Advisory Panel and the Fast Track Action Committee on Select Agent Regulations.提升美国生物安全与生物安保水平:重新审视联邦专家安全咨询小组及选择剂法规快速行动委员会的建议。
Appl Biosaf. 2023 Mar 1;28(1):43-54. doi: 10.1089/apb.2022.0025. Epub 2023 Mar 6.
10
Biosafety and Biosecurity Challenges Facing Veterinary Diagnostic Laboratories in Lower-Middle Income Countries in Southeast Asia: A Case Study of Thailand.东南亚中低收入国家兽医诊断实验室面临的生物安全和生物安保挑战:以泰国为例
Appl Biosaf. 2019 Dec;24(4):220-230. doi: 10.1177/1535676019869771. Epub 2019 Aug 19.

引用本文的文献

1
Exploring temperature-dependent transcriptomic adaptations in Yersinia pestis using direct cDNA sequencing by Oxford Nanopore Technologies.利用牛津纳米孔技术直接进行cDNA测序探索鼠疫耶尔森菌中温度依赖性转录组适应性。
Sci Rep. 2025 Jul 1;15(1):20564. doi: 10.1038/s41598-025-05662-1.
2
Pathogenicity and virulence of chikungunya virus.基孔肯雅病毒的致病性和毒力。
Virulence. 2024 Dec;15(1):2396484. doi: 10.1080/21505594.2024.2396484. Epub 2024 Sep 1.
3
A Systematized Overview of Published Reviews on Biological Hazards, Occupational Health, and Safety.

本文引用的文献

1
Possession, Use, and Transfer of Select Agents and Toxins; Biennial Review of the List of Select Agents and Toxins and Enhanced Biosafety Requirements. Final rule.特定病原体和毒素的占有、使用及转移;特定病原体和毒素清单的两年期审查及强化生物安全要求。最终规则。
Fed Regist. 2017 Jan 19;82(12):6278-94.
2
Poliovirus Studies during the Endgame of the Polio Eradication Program.脊髓灰质炎根除计划收官阶段的脊髓灰质炎病毒研究
Jpn J Infect Dis. 2017 Jan 24;70(1):1-6. doi: 10.7883/yoken.JJID.2016.356. Epub 2016 Oct 31.
3
Survey of laboratory-acquired infections around the world in biosafety level 3 and 4 laboratories.
已发表的关于生物危害、职业健康与安全的综述的系统概述。
Saf Health Work. 2023 Dec;14(4):347-357. doi: 10.1016/j.shaw.2023.10.008. Epub 2023 Oct 21.
4
Risk assessment and bioburden evaluation of Agrobacterium tumefaciens-mediated transient protein expression in plants using the CaMV35S promoter.利用 CaMV35S 启动子评估农杆菌介导的植物瞬时蛋白表达的风险和生物负荷。
BMC Biotechnol. 2023 Jun 7;23(1):14. doi: 10.1186/s12896-023-00782-w.
5
The Development of Diagnostic and Vaccine Strategies for Early Detection and Control of Human Brucellosis, Particularly in Endemic Areas.人类布鲁氏菌病早期检测与控制的诊断及疫苗策略的发展,特别是在流行地区。
Vaccines (Basel). 2023 Mar 14;11(3):654. doi: 10.3390/vaccines11030654.
6
Predicting and Anti-SARS-CoV-2 Activities of Antivirals by Intracellular Bioavailability and Biochemical Activity.通过细胞内生物利用度和生化活性预测抗病毒药物及抗SARS-CoV-2活性
ACS Omega. 2022 Nov 29;7(49):45023-45035. doi: 10.1021/acsomega.2c05376. eCollection 2022 Dec 13.
7
Assessment of biorisk management systems in high containment laboratories, 18 countries in Europe, 2016 and 2017.评估高防护实验室的生物风险管理系统,欧洲 18 个国家,2016 年和 2017 年。
Euro Surveill. 2020 Sep;25(36). doi: 10.2807/1560-7917.ES.2020.25.36.2000089.
8
Biodefense Implications of New-World Hantaviruses.新大陆汉坦病毒的生物防御意义
Front Bioeng Biotechnol. 2020 Aug 7;8:925. doi: 10.3389/fbioe.2020.00925. eCollection 2020.
9
Inaugural editorial: Towards evidence-based biosafety and biosecurity.创刊社论:迈向循证生物安全与生物安保
J Biosaf Biosecur. 2019 Mar;1(1):1-2. doi: 10.1016/j.jobb.2019.01.008. Epub 2019 Feb 20.
10
Biosafety and biosecurity capacity building: insights from implementation of the NUITM-KEMRI biosafety training model.生物安全与生物安保能力建设:NUITM-肯尼亚医学研究协会生物安全培训模式实施的见解
Trop Med Health. 2018 Aug 8;46:30. doi: 10.1186/s41182-018-0108-7. eCollection 2018.
全球生物安全3级和4级实验室实验室感染情况调查。
Eur J Clin Microbiol Infect Dis. 2016 Aug;35(8):1247-58. doi: 10.1007/s10096-016-2657-1. Epub 2016 May 27.
4
Biological Risks and Laboratory-Acquired Infections: A Reality That Cannot be Ignored in Health Biotechnology.生物风险和实验室获得性感染:健康生物技术中不容忽视的现实。
Front Bioeng Biotechnol. 2015 Apr 28;3:56. doi: 10.3389/fbioe.2015.00056. eCollection 2015.
5
The hidden face of academic researches on classified highly pathogenic microorganisms.关于高致病性分类微生物学术研究的隐藏面。
Infect Genet Evol. 2015 Jan;29:26-34. doi: 10.1016/j.meegid.2014.10.028. Epub 2014 Nov 7.
6
Establishment of Biosafety Level-3 (BSL-3) laboratory: important criteria to consider while designing, constructing, commissioning & operating the facility in Indian setting.生物安全三级(BSL-3)实验室的建立:在印度环境中设计、建造、调试和运营该设施时需要考虑的重要标准。
Indian J Med Res. 2014 Aug;140(2):171-83.
7
Comparison and analysis of biological agent category lists based on biosafety and biodefense.基于生物安全和生物防御的生物制剂类别清单的比较与分析。
PLoS One. 2014 Jun 30;9(6):e101163. doi: 10.1371/journal.pone.0101163. eCollection 2014.
8
State-of-the-art in biosafety and biosecurity in European countries.欧洲国家生物安全与生物安保的最新进展。
Arch Immunol Ther Exp (Warsz). 2014 Jun;62(3):169-78. doi: 10.1007/s00005-014-0290-1. Epub 2014 May 13.
9
BSL-3 laboratory practices in the United States: comparison of select agent and non-select agent facilities.美国的生物安全三级实验室操作:特定病原体与非特定病原体设施的比较
Biosecur Bioterror. 2014 Jan-Feb;12(1):1-7. doi: 10.1089/bsp.2013.0060.
10
Factors influencing biosafety level and LAI among the staff of medical laboratories.影响医学实验室工作人员生物安全水平和实验室感染率的因素。
Med Pr. 2013;64(4):473-86. doi: 10.13075/mp.5893.2013.0056.